GB25

GB25 is an investigational trispecific antibody developed by Kexing Biopharm (also known as Shandong Kexing Bioproducts) for the treatment of colorectal cancer. Currently in Phase 3 clinical development, this biologic agent is designed to simultaneously engage three different targets, a strategy often employed in oncology to improve tumor specificity and recruit immune effector cells to the tumor microenvironment. While the specific molecular targets of GB25 remain proprietary and have not been publicly disclosed, its advanced clinical stage highlights its importance in Kexing's innovative antibody pipeline, which focuses on recombinant proteins and multi-specific antibody therapeutics for solid tumors and other diseases.

Other names

Trispecific antibody for Colorectal Cancer